TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate we’ll pursue our common goal: to bring Microlyse into clinical development! Read the press release here
January 2022 – Our new clot-buster Microlyse is now published in- and on the cover of Blood. You can: Listen to the Blood podcast (7:15 – 12:30) Download our paper here (before March 18, 2022) click to enlarge
June 2021 – TargED Biopharmaceuticals today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). With his extensive experience in the clinical development of new medical products, Ludo will support the company’s transition from preclinical to clinical stage company.
We are proud to share that TargED joins forces with Good Biomarker Sciences (GBS) to develop a biomarker assay that supports TargED lead compound, Microlyse towards and throughout clinical studies. The collaboration is supported with a MIT R&D grant from the Economic Board Utrecht and… Read More »TargED and GBS Leiden partner up and were granted MIT R&D
Again, we can share some thrilling news! TargED is awarded the @NWO Take Off II loan (€250.000) to further develop its clot-busting lead compound, Microlyse, which could ultimately help millions of patients around the globe. What a welcome reward to a remarkable year 2020! See… Read More »TargED is granted the NWO Take Off II loan
November 24th, 2020 – We are very proud to announce the closing of a €1.35m Seed investment from Curie Capital, Utrecht Health Seed Fund and Fonds InvesteringsRijpe STarts (FIRST), supported by additional funding from Health Holland. Pleas find the full press release attached!
July 7th, 2020 – After two years of working on what has been purely a scientific endeavour, Coen Maas, Steven de Maat, Kristof Vercruysse and Marc van Moorsel have now officially founded TargED Biopharmaceuticals B.V. as UMC Utrecht spin-off. Why this name? Because TargED actually… Read More »FOUNDED